AstraZeneca Is a Cancer Leader. Obesity Could Be a Bonus.

Healthcare investors have been showing a strong preference for obesity-focused drugmakers. However, AstraZeneca, a leading player in the cancer market, offers a more reasonable valuation, making it a better investment option. Additionally, there is potential for AstraZeneca to gain a share in the weight-loss market, providing further upside for its shareholders. Investors should consider AstraZeneca as an attractive investment opportunity in the pharmaceutical industry.